AveXis (AVXS) IPO Opens Down 10%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street dips as spiking crude prices revive fears of inflation, rate hike
- The Warsh pivot markets didn't expect
- Oil rises over 2% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
AveXis Announces Pricing of Initial Public Offering
February 10, 2016 9:33 PM ESTCHICAGO, Feb. 10, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (Nasdaq: AVXS), a clinical stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the pricing of its initial public offering of 4,750,000 shares of common stock at an initial public offering price of $20.00 per share, before underwriting discounts. In addition, AveXis has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by AveXis.... More
